Factors Associated With Clinical Remission of Skin Disease in Dermatomyositis.

about

Factors Associated With Clinical Remission of Skin Disease in Dermatomyositis.

Item

http://www.wikidata.org/entity/Q46134512

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Factors Associated With Clinical Remission of Skin Disease in Dermatomyositis.

@en

Factors Associated With Clinical Remission of Skin Disease in Dermatomyositis.

@nl

type

Item

label

Factors Associated With Clinical Remission of Skin Disease in Dermatomyositis.

@en

Factors Associated With Clinical Remission of Skin Disease in Dermatomyositis.

@nl

prefLabel

Factors Associated With Clinical Remission of Skin Disease in Dermatomyositis.

@en

Factors Associated With Clinical Remission of Skin Disease in Dermatomyositis.

@nl

P1476

Factors Associated With Clinical Remission of Skin Disease in Dermatomyositis.

@en

P2093

David F Fiorentino

http://www.w3.org/2001/XMLSchema#string

Livia Casciola-Rosen

http://www.w3.org/2001/XMLSchema#string

Lorinda Chung

http://www.w3.org/2001/XMLSchema#string

Paige W Wolstencroft

http://www.w3.org/2001/XMLSchema#string

Shufeng Li

http://www.w3.org/2001/XMLSchema#string

P2860

Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies

Aging of the innate immune system

Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis

Persistent association of nailfold capillaroscopy changes and skin involvement over thirty-six months with duration of untreated disease in patients with juvenile dermatomyositis.

Modification of the cutaneous dermatomyositis disease area and severity index, an outcome instrument.

Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ.

Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis.

Polymyositis and dermatomyositis (second of two parts).

Polymyositis and dermatomyositis (first of two parts).

Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases

P31

scholarly article

P356

10.1001/JAMADERMATOL.2017.3758

http://www.w3.org/2001/XMLSchema#string

P407

English

P577

2017-11-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29114741

http://www.w3.org/2001/XMLSchema#string

P921

dermatomyositis

P932

5833585

http://www.w3.org/2001/XMLSchema#string